The prevalence of lupus anticoagulant (LAC) and its relation with reported clinical associations has been determined in 55 patients with systemic lupus erythematosus (SLE) from northern Indiawhowere studiedprospectively. Kaolin clotting time was used to screen for LAC, which was detected in seven (13%h) (KCT) were similarly excluded. At the time of study 48 patients were taking low dose prednisolone (less than 10 mg in 37 and 10-15 mg in 11 patients). Seven patients were taking only antimalarial drugs and paracetamol.
The existence of spontaneously acquired anticoagulant activity in systemic lupus erythematosus (SLE) 23 was much less than that (65%) reported by Exner et al'5 using the same test. They studied 17 patients referred for haematological problems, however, suggesting a selection bias. Some underestimation in our study could not be ruled out as most patients had received immunosuppressive treatment in the past. None of our patients was receiving cytotoxic drugs and high dose corticosteroids at the time of study, however. Until the various screening tests are standardised and definite criteria laid down for detection of LAC, the exact prevalence of LAC cannot be confirmed.
The prevalence of LAC was very high in younger patients (63% in juvenile SLE as compared with 4% in patients aged more than 16). A similar observation has been made by Lechner.24 The patients with LAC presented with a shorter duration of illness than those without it. This might be due to the presence of a more severe illness in these patients, necessitating a visit to a tertiary hospital early in the course of illness.
A comparison of the clinical profile in the two subgroups shows a higher incidence of thrombosis in those with LAC X2=397; p<0-05) Previous studies have also shown a strong association between LAC and thrombotic events. 4 
